Correlates of higher-dose opioid medication use for low back pain in primary care

Amy Kobus, David H. Smith, Benjamin Morasco, Eric S. Johnson, Xiuhai Yang, Amanda F. Petrik, Richard (Rick) Deyo

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Factors associated with high-dose opioid therapy for noncancer pain are poorly understood. We documented the prevalence of high-dose opioid use as well as associated demographic, clinical, and health service utilization correlates among low back pain patients. Patients prescribed higher doses of opioids (≥100 mg/day morphine equivalent at last dispensing; n = 453) and receiving opioids for 90+ consecutive days were compared to 2 groups: lower-dose opioid group (1-99 mg/day; n = 4,815) or no-opioid group (n = 10,184). Higher-dose opioid use occurred in 2.9% of patients who received any opioids and in 8.6% of patients who received opioids long-term. The median dose in the higher-dose group was 180.0 mg/day. Compared to the no-opioid group, higher-dose users reported poorer health. Compared to either comparison group, patients in the higher-dose group had higher rates of mental health and substance use disorders, concurrent sedative-hypnotic use (60.5%; n = 274), and health service utilization. After adjusting for select covariates, male gender (odds ratio [OR] = 1.68, 95% confidence interval [CI] = 1.37-2.06), higher comorbidity, Medicare coverage (OR = 1.65, 95% CI = 1.22-2.23), any mental health or substance use diagnosis (OR = 1.58, 95% CI = 1.28-1.95), co-prescriptions of sedative-hypnotics (OR = 1.75, 95% CI = 1.42-2.16), and more emergency department and specialty pain clinic visits were associated with higher likelihood of high-dose prescriptions. Perspective: Higher-dose opioid therapy is being prescribed to 8.6% of back pain patients who receive long-term opioids. These patients had higher mental health and medical comorbidities and co-prescriptions of sedative-hypnotics, raising potential safety concerns.

Original languageEnglish (US)
Pages (from-to)1131-1138
Number of pages8
JournalJournal of Pain
Volume13
Issue number11
DOIs
StatePublished - Nov 2012

Fingerprint

Low Back Pain
Opioid Analgesics
Primary Health Care
Hypnotics and Sedatives
Odds Ratio
Confidence Intervals
Prescriptions
Mental Health
Health Services
Comorbidity
Pain Clinics
Back Pain
Ambulatory Care
Medicare
Morphine
Substance-Related Disorders
Hospital Emergency Service
Demography
Safety
Pain

Keywords

  • back pain
  • Chronic pain
  • epidemiology
  • opioids
  • pain/drug therapy

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Neurology
  • Clinical Neurology

Cite this

Correlates of higher-dose opioid medication use for low back pain in primary care. / Kobus, Amy; Smith, David H.; Morasco, Benjamin; Johnson, Eric S.; Yang, Xiuhai; Petrik, Amanda F.; Deyo, Richard (Rick).

In: Journal of Pain, Vol. 13, No. 11, 11.2012, p. 1131-1138.

Research output: Contribution to journalArticle

Kobus, Amy ; Smith, David H. ; Morasco, Benjamin ; Johnson, Eric S. ; Yang, Xiuhai ; Petrik, Amanda F. ; Deyo, Richard (Rick). / Correlates of higher-dose opioid medication use for low back pain in primary care. In: Journal of Pain. 2012 ; Vol. 13, No. 11. pp. 1131-1138.
@article{26448d3f940d45bab7ca7b027ebb314a,
title = "Correlates of higher-dose opioid medication use for low back pain in primary care",
abstract = "Factors associated with high-dose opioid therapy for noncancer pain are poorly understood. We documented the prevalence of high-dose opioid use as well as associated demographic, clinical, and health service utilization correlates among low back pain patients. Patients prescribed higher doses of opioids (≥100 mg/day morphine equivalent at last dispensing; n = 453) and receiving opioids for 90+ consecutive days were compared to 2 groups: lower-dose opioid group (1-99 mg/day; n = 4,815) or no-opioid group (n = 10,184). Higher-dose opioid use occurred in 2.9{\%} of patients who received any opioids and in 8.6{\%} of patients who received opioids long-term. The median dose in the higher-dose group was 180.0 mg/day. Compared to the no-opioid group, higher-dose users reported poorer health. Compared to either comparison group, patients in the higher-dose group had higher rates of mental health and substance use disorders, concurrent sedative-hypnotic use (60.5{\%}; n = 274), and health service utilization. After adjusting for select covariates, male gender (odds ratio [OR] = 1.68, 95{\%} confidence interval [CI] = 1.37-2.06), higher comorbidity, Medicare coverage (OR = 1.65, 95{\%} CI = 1.22-2.23), any mental health or substance use diagnosis (OR = 1.58, 95{\%} CI = 1.28-1.95), co-prescriptions of sedative-hypnotics (OR = 1.75, 95{\%} CI = 1.42-2.16), and more emergency department and specialty pain clinic visits were associated with higher likelihood of high-dose prescriptions. Perspective: Higher-dose opioid therapy is being prescribed to 8.6{\%} of back pain patients who receive long-term opioids. These patients had higher mental health and medical comorbidities and co-prescriptions of sedative-hypnotics, raising potential safety concerns.",
keywords = "back pain, Chronic pain, epidemiology, opioids, pain/drug therapy",
author = "Amy Kobus and Smith, {David H.} and Benjamin Morasco and Johnson, {Eric S.} and Xiuhai Yang and Petrik, {Amanda F.} and Deyo, {Richard (Rick)}",
year = "2012",
month = "11",
doi = "10.1016/j.jpain.2012.09.003",
language = "English (US)",
volume = "13",
pages = "1131--1138",
journal = "Journal of Pain",
issn = "1526-5900",
publisher = "Churchill Livingstone",
number = "11",

}

TY - JOUR

T1 - Correlates of higher-dose opioid medication use for low back pain in primary care

AU - Kobus, Amy

AU - Smith, David H.

AU - Morasco, Benjamin

AU - Johnson, Eric S.

AU - Yang, Xiuhai

AU - Petrik, Amanda F.

AU - Deyo, Richard (Rick)

PY - 2012/11

Y1 - 2012/11

N2 - Factors associated with high-dose opioid therapy for noncancer pain are poorly understood. We documented the prevalence of high-dose opioid use as well as associated demographic, clinical, and health service utilization correlates among low back pain patients. Patients prescribed higher doses of opioids (≥100 mg/day morphine equivalent at last dispensing; n = 453) and receiving opioids for 90+ consecutive days were compared to 2 groups: lower-dose opioid group (1-99 mg/day; n = 4,815) or no-opioid group (n = 10,184). Higher-dose opioid use occurred in 2.9% of patients who received any opioids and in 8.6% of patients who received opioids long-term. The median dose in the higher-dose group was 180.0 mg/day. Compared to the no-opioid group, higher-dose users reported poorer health. Compared to either comparison group, patients in the higher-dose group had higher rates of mental health and substance use disorders, concurrent sedative-hypnotic use (60.5%; n = 274), and health service utilization. After adjusting for select covariates, male gender (odds ratio [OR] = 1.68, 95% confidence interval [CI] = 1.37-2.06), higher comorbidity, Medicare coverage (OR = 1.65, 95% CI = 1.22-2.23), any mental health or substance use diagnosis (OR = 1.58, 95% CI = 1.28-1.95), co-prescriptions of sedative-hypnotics (OR = 1.75, 95% CI = 1.42-2.16), and more emergency department and specialty pain clinic visits were associated with higher likelihood of high-dose prescriptions. Perspective: Higher-dose opioid therapy is being prescribed to 8.6% of back pain patients who receive long-term opioids. These patients had higher mental health and medical comorbidities and co-prescriptions of sedative-hypnotics, raising potential safety concerns.

AB - Factors associated with high-dose opioid therapy for noncancer pain are poorly understood. We documented the prevalence of high-dose opioid use as well as associated demographic, clinical, and health service utilization correlates among low back pain patients. Patients prescribed higher doses of opioids (≥100 mg/day morphine equivalent at last dispensing; n = 453) and receiving opioids for 90+ consecutive days were compared to 2 groups: lower-dose opioid group (1-99 mg/day; n = 4,815) or no-opioid group (n = 10,184). Higher-dose opioid use occurred in 2.9% of patients who received any opioids and in 8.6% of patients who received opioids long-term. The median dose in the higher-dose group was 180.0 mg/day. Compared to the no-opioid group, higher-dose users reported poorer health. Compared to either comparison group, patients in the higher-dose group had higher rates of mental health and substance use disorders, concurrent sedative-hypnotic use (60.5%; n = 274), and health service utilization. After adjusting for select covariates, male gender (odds ratio [OR] = 1.68, 95% confidence interval [CI] = 1.37-2.06), higher comorbidity, Medicare coverage (OR = 1.65, 95% CI = 1.22-2.23), any mental health or substance use diagnosis (OR = 1.58, 95% CI = 1.28-1.95), co-prescriptions of sedative-hypnotics (OR = 1.75, 95% CI = 1.42-2.16), and more emergency department and specialty pain clinic visits were associated with higher likelihood of high-dose prescriptions. Perspective: Higher-dose opioid therapy is being prescribed to 8.6% of back pain patients who receive long-term opioids. These patients had higher mental health and medical comorbidities and co-prescriptions of sedative-hypnotics, raising potential safety concerns.

KW - back pain

KW - Chronic pain

KW - epidemiology

KW - opioids

KW - pain/drug therapy

UR - http://www.scopus.com/inward/record.url?scp=84868132599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868132599&partnerID=8YFLogxK

U2 - 10.1016/j.jpain.2012.09.003

DO - 10.1016/j.jpain.2012.09.003

M3 - Article

C2 - 23117108

AN - SCOPUS:84868132599

VL - 13

SP - 1131

EP - 1138

JO - Journal of Pain

JF - Journal of Pain

SN - 1526-5900

IS - 11

ER -